secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2025-02-07T23:59:59+00:00
Accession:  0001493152-25-005302
Event type: leadership
Sentiment:  positive
Materiality: 0.25
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma appoints Evelyn D'An as independent director and Audit Committee Chair
--------------------------------------------------------------------------------

- Evelyn D'An appointed to board effective February 5, 2025 as independent director and Audit Committee Chair.
- Ms. D'An is a former Ernst & Young partner with 18 years of experience, currently President of D'An Financial Services.
- She also serves on boards of Zoomcar (ZCAR), Backblaze (BLZE), and GHD Group (private).
- No related party transactions; compensated under standard non-employee director plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225005302/0001493152-25-005302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225005302/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-005302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer